Lin Shuhai's research group co-published a research paper in the "Proceedings of the National Academy of Sciences" to identify metabolites that regulate the level of new crown antibodies

Since the outbreak of COVID-19, Lin Shuhai's research group has carried out a series of metabolism-related studies, and has cooperated to identify metabolic markers in different stages of COVID-19 (National Science Review 2020), as well as the abnormal analysis of milk proteins and metabolites in maternal patients with COVID-19.

On August 9, Lin Shuhai's group published a research paper entitled Plasma metabolome and cytokine profile reveal glycylproline modulating antibody fading in convalescent COVID-19 patients in PNAS

In this research work, Lin Shuhai's research group and the cooperative team collected the plasma samples of recovered subjects with COVID-19 carrying antibodies, recovered subjects with COVID-19 but the antibodies subsided, and healthy volunteers, and carried out targeted metabolomics and quantification of inflammatory factors.

Since glycylproline can be catalyzed by DPP4, the use of sitagliptin (DPP4 inhibitor) can reduce the level of glycylproline

Therefore, the researchers used a single dose of SARS-CoV-2 RBD protein fragment intraperitoneally injected into BALB/c female mice and detected immune cell subsets (germinal center B cells (GC B cells), follicular helper T cells (Tfh) and plasma cells to elucidate that glycylproline can modulate antibody immune responses

This study shows that there are significant differences in plasma glycylproline concentrations in subjects with different levels of COVID-19 antibodies, and the level of neutralizing antibodies in mammals vaccinated against COVID-19 is indeed regulated by glycylproline, suggesting that glycylproline Aminoacylproline can be used to identify or differentiate subjects vaccinated against COVID-19 with different antibody levels

The School of Life Sciences of Xiamen University is the first completion unit

Original link:Lin Shuhai Research Group)